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Introduction
We recently observed a remarkably increased synovial
infiltration with c-kit-positive mast cells in non-psoriatic
and psoriatic spondyloarthritis (SpA) versus rheumatoid
arthritis (RA).
Aim
As these mast cells were not degranulated, we investigated
whether they could contribute to synovial inflammation by
cytokine production, with special focus on IL-17.
Patients and methods
Synovial tissue biopsies from active non-psoriatic and
psoriatic SpA (n=10) and RA (n=10) were stained with
mouse anti-c-kit, goat anti-IL-17 and mouse anti-mast
cell tryptase (MCT) by immunohistochemistry and dou-
ble immunofluorescence. The effect of inhibition of
c-kit tyrosine kinase by imatinib mesylate on proinflam-
matory cytokine production was tested in vitro on fresh
synovial biopsies from 14 SpA patients.
Results
Mast cells were identified in synovial tissue by immunos-
taining for c-kit or mast cell tryptase. Single immunos-
taining for IL-17 showed multiple single positive
mononuclear cells in all types of arthritis. Double immu-
nofluorescence indicated a striking colocalization of IL-
17 and mast cell tryptase in non-psoriatic and psoriatic
SpA. Quantification by manual counting confirmed that
a median of 65% of the synovial mast cells in SpA express
IL-17. In contrast, only 26% of the mast cells expressed
IL-17 in RA (p=0.015). Moreover, mast cells were the
main IL-17 producing cell subset in SpA (60-70%) but
not in RA (20-30%)(p=0.036). In order to investigate the
role of cytokine production by mast cells in the synovial
inflammation in SpA, we used imatinib mesylate to block
c-kit tyrosine kinase in ex vivo synovial tissue cultures.
C-kit blockade strongly reduced not only IL-6 and IL-8
but also IL-17A production by SpA synovial biopsies.
Conclusion
The increase in synovial mast cells in SpA synovitis, their
augmented production of IL-17, and the downregulation of
cytokine production by targeting mast cells ex vivo strongly
suggest that mast cells contribute to synovial inflammation
in SpA and are an attractive therapeutic target.
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